36
Hansoh Pharma
3692.HK·HKEXLianyungang CNFounded 199512,000 employees
Large CappharmaPublicOncologyCNSMetabolic
Platform: SM & Bio
Market Cap
$12B
All Drugs
5
Clinical Trials
8
Failed / Terminated
2
FDA Approved
1
Stock Price & Catalysts (3692.HK)
Loading 3692.HK stock data...
Drug Pipeline (5 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 369-8021 | 369-8021 | Approved | 2 | BTK | DMD | ||
| 369-4107 | 369-4107 | Phase 2 | 1 | TNFα | DravetIPF | ||
| Niramavacamten | 369-5803 | Phase 2 | 1 | SGLT2 | IgANMeso | ||
| 369-789 | 369-789 | Phase 3 | 2 | PI3Kα | FTDMS | ||
| Mavutuximab | 369-1858 | Phase 2/3 | 2 | PI3Kα | ACCSCLC |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Hansoh Pharma trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (8)